INZY — Inozyme Pharma Share News
0.000.00%
Last trade - 00:00- $257.60m
- $219.11m
Brief: Inozyme Pharma Reports Third Quarter 2021 Financial Results And Provides Business Highlights
Inozyme Pharma Inc expected to post a loss of 61 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:46 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
Brief: Inozyme Pharma Inc Files For Mixed Shelf Of Upto $200 Mln
Inozyme Pharma Inc reports results for the quarter ended in June - Earnings Summary
Brief: Inozyme Pharma Reports Q2 2021 Financial Results
Brief: Inozyme Pharma Receives Orphan Drug Designation For Inz-701 From The European Medicines Agency For The Treatment Of Abcc6 Deficiency
Brief: Inozyme Pharma Announces Appointment Of Gayle Gironda As Senior Vice President, Human Resources
Brief: Inozyme Announces Acceptance Of First European Clinical Trial Application For Phase 1/2 Clinical Trial Of Inz-701 In Abcc6 Deficiency
Inozyme Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inozyme Pharma Reports Q1 Loss Per Share Of $0.47
Brief: Inozyme Pharma Presents Preclinical Data Suggesting Utility Of INZ-701
Brief: Inozyme Pharma Publishes Data Supporting INZ-701 As A Potential Treatment For ENPP1 Deficiency
Brief: Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency
Brief: Inozyme Pharma Expects To Initiate Phase 1/2 Trials Of Inz-701 For ENPP1 Deficiency In First Half Of Year
Inozyme: Up on UK, U.S. nod for human trials of mineralization disorder drug
Brief: Inozyme Pharma Announces Authorization To Proceed In U.S. And U.K. With Phase 1/2 Clinical Trial Of Inz-701 For The Treatment Of Enpp1 Deficiency
Brief: Inozyme Pharma Reports Third Quarter 2020 Financial Results And Provides Business Highlights